Your biological age test returns a number. Here is what it can support.

Biological age testing has become an ordinary consumer purchase. A saliva or blood sample goes off, and a number comes back: an age, a gap between that age and the one on your passport, an age for individual organs, or a "pace of ageing" expressed as years accrued per calendar year [s3]. Longevity clinics and direct-to-consumer companies now promote these tests, frequently with the promise that targeted interventions can slow the ageing process [s1].

The question worth asking before paying is narrower than "is this real?" It is: what decision can this number support?

What the number is

A biological-age score is a model output. It takes biomarkers and other health data and translates them into an age-shaped result [s3]. That translation is the source of both its appeal and its problems: age is a familiar and legally salient classification that already structures access to employment, insurance, benefits and care [s3].

The tests do not measure a single underlying quantity. Different clocks are built for different purposes — some to estimate accumulated damage, some to estimate the current rate of deterioration — and they are trained on different data. A commentary published in August 2026 notes that expert panels have converged on which biomarkers are worth tracking as outcomes in ageing intervention trials, and have concluded that no single biomarker suffices, which leaves a composite as the only viable path [s4].

That conclusion is from the research side of the field, where the incentive is to find something that works. The consumer side sells single readings.

The case for the tests

There is a real argument for measurement, and it is not a scientific one. Longevity clinics respond to a demand that traditional healthcare has not met, and their clients are encouraged to track, monitor and reflect on their own health metrics rather than receive care passively [s2]. When people are engaged in understanding their own biology, adherence improves and lifestyle change — still the most robust intervention for healthy ageing — becomes more likely [s2].

A number you check is a number you might act on. If the action is exercise, sleep and diet, the mechanism by which the test helped hardly matters.

The case against relying on it

Three problems are worth knowing about.

The clocks do not reliably respond to interventions. A 2026 study built epigenetic predictors specifically trained on cellular senescence, after finding that existing clocks showed inconsistent associations with senescence and no reduction following senolytic treatment [s5]. Senescence, age and mortality risk turned out to intersect at only 9,363 of 396,333 CpG sites analysed — 2.4% of the methylome examined [s5]. All three of the new predictors stayed the same or accelerated after senolytic treatment, in living animals and in cell culture [s5]. The authors write that this challenges the assumption that ageing biomarkers decrease after geroscience interventions [s5].

If a marker does not fall when an intervention demonstrably does what it was designed to do, a falling marker is not proof that something worked, and a static one is not proof that it failed.

The price is not proportionate to the information. Annual memberships at longevity clinics commonly run from €10,000 to €50,000, with some executive health packages exceeding €100,000 [s2]. A typical client may undergo genomic sequencing, multi-omics profiling, advanced imaging, full-body scans, immune assessments, microbiome analysis and epigenetic testing [s2]. These clinics are not embedded within mainstream medical practice [s2], which means the results generally arrive without the interpretive infrastructure that surrounds a clinical test.

The distributional point follows: at those prices the service reaches wealthy people, while the individuals at greatest risk of premature ageing typically come from the lowest socioeconomic levels [s2].

Nobody has agreed what the number means. Biological age tests, longevity clinics and consumer wearables now reach millions of people, and no shared framework exists to tell an individual what those numbers mean or what to do about them [s4]. The proposal in that paper is to borrow the solution cardiovascular medicine found — a scored composite of behavioural and biological components administered in primary care, with seven of eight components requiring only a questionnaire, a bedside test and routine bloods [s4]. That is a proposal, not a standard.

The use nobody has agreed to yet

The forward-looking concern is what happens when institutions start treating these scores as authoritative. Healthcare institutions can give biological-age scores clinical and social authority simply by interpreting them, entering them into records and permitting secondary use [s3]. Actuarial literature has begun to examine the scores, though widespread discriminatory use has not been documented — the concern is anticipatory rather than observed [s3]. Social disadvantage is itself associated with accelerated biological ageing, which creates a route by which prior injustice could shape later decisions about eligibility or cost [s3].

The insurance-medicine review that asked whether biological clocks are ready for prime time framed the same question from the underwriter's side: is the testing scientifically valid, and is it useful [s1].

The honest summary

A biological age result is a modelled estimate, built from markers that predict population-level risk, sold to individuals as a personal verdict, with no agreed interpretation and — on current evidence — no dependable response to the things people buy the test to evaluate. It is defensible as a prompt. It is not yet a measurement you should let anyone make a decision about you with.

This article describes research findings and is not medical advice.

Sources

1. [s1] Biological Clocks: Ready for Prime Time? Journal of Insurance Medicine, June 15, 2026. https://doi.org/10.17849/insm-53-2-1-5.1B
2. [s2] Longevity clinics: between promise and peril. Aging (Albany NY), published online October 13, 2025. https://doi.org/10.18632/aging.206330
3. [s3] Biological-Age Scoring and the Risk of Algorithmic Age Discrimination: An Institutional Ethics Framework. HEC Forum, published online August 20, 2026. https://doi.org/10.1007/s10730-026-09606-8
4. [s4] An aging essential 8: closing the gap between geroscience and the public it serves. Biogerontology, August 26, 2026. https://doi.org/10.1007/s10522-026-10497-y
5. [s5] DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment. Aging Cell, published online February 2026. https://doi.org/10.1111/acel.70430